ACIU AC Immune SA

9.86
0  -1%
Previous Close 9.98
Open 10.00
Price To book 4.00
Market Cap 561.25M
Shares 56,922,000
Volume 8,231
Short Ratio 26.73
Av. Daily Volume 44,698

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Second Phase 3 trial initiation announced February 28, 2017.
Crenezumab - CREAD 2
Alzheimer’s disease
Phase 2 trial to commence 2017. IPO September 23, 2016.
ACI-35 (anti-tau vaccine)
Alzheimer’s disease
Phase 1/2 ongoing. IPO September 23, 2016. Decision on future trials due within next few months - as of March 17, 2017.
ACI-24 (anti-Abeta vaccine)
Alzheimer’s disease
Phase 3 trial commennced 1Q 2016. Phase 2 trial did not meet co-primary endpoints. IPO September 23, 2016. Data due 2020.
Crenezumab - CREAD 1
Alzheimer’s disease

Latest News

  1. Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer at International Alzheimer's Conference
  2. AC Immune SA :ACIU-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017
  3. AC IMMUNE PROVIDES TWELVE UPDATES ON ITS PIPELINE AT THE INTERNATIONAL CONFERENCE ON ALZHEIMER'S AND PARKINSON'S DISEASES
  4. AC IMMUNE REPORTS FULL YEAR 2016 FINANCIAL RESULTS AND R&D UPDATE
  5. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : March 7, 2017
  6. Roche to start new trial of AC Immune drug against Alzheimer's
  7. AC IMMUNE PARTNER GENENTECH TO START SECOND PHASE 3 CLINICAL TRIAL FOR ALZHEIMER'S THERAPY CRENEZUMAB
  8. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : January 16, 2017
  9. AC Immune SA – Value Analysis (NASDAQ:ACIU) : December 23, 2016
  10. AC Immune SA breached its 50 day moving average in a Bearish Manner : ACIU-US : December 22, 2016
  11. Here is What Hedge Funds Think About AC Immune Ltd (ACIU)
  12. AC Immune SA breached its 50 day moving average in a Bullish Manner : ACIU-US : December 12, 2016
  13. Astra, Lilly stick with Alzheimer's approach despite setback
  14. AC Immune SA :ACIU-US: Earnings Analysis: Q3, 2016 By the Numbers : November 18, 2016
  15. Eli Lilly's Alzheimer's Drug Study Results Are Coming -- Here's What Investors Need to Know
  16. Alzheimer's Remains a Top Priority for Big Pharma
  17. AC Immune SA: Price momentum supported by strong fundamentals
  18. Here’s A Look At AC Immune Ltd (ACIU)’s Alzheimer’s Candidate, Crenezumab
  19. Biotech IPOs: Outliers, Value Creation And The Dispersion Of Returns